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Abstract
Background: Signalling pathways are the cornerstone on understanding cell function and predicting cell behavior.
Recently, logical models of canonical pathways have been optimised with high-throughput phosphoproteomic
data to construct cell-type specific pathways. However, less is known on how signalling pathways can be linked to
a cellular response such as cell growth, death, cytokine secretion, or transcriptional activity.
Results: In this work, we measure the signalling activity (phosphorylation levels) and phenotypic behavior (cytokine
secretion) of normal and cancer hepatocytes treated with a combination of cytokines and inhibitors. Using the two
datasets, we construct “extended” pathways that integrate intracellular activity with cellular responses using a
hybrid logical/data-driven computational approach. Boolean logic is used whenever a priori knowledge is
accessible (i.e., construction of canonical pathways), whereas a data-driven approach is used for linking cellular
behavior to signalling activity via non-canonical edges. The extended pathway is subsequently optimised to fit
signalling and behavioural data using an Integer Linear Programming formulation. As a result, we are able to
construct maps of primary and transformed hepatocytes downstream of 7 receptors that are capable of explaining
the secretion of 22 cytokines.
Conclusions: We developed a method for constructing extended pathways that start at the receptor level and via
a complex intracellular signalling pathway identify those mechanisms that drive cellular behaviour. Our results
constitute a proof-of-principle for construction of “extended pathways” that are capable of linking pathway activity
to diverse responses such as growth, death, differentiation, gene expression, or cytokine secretion.
Background
Construction of signalling pathways is a major endea-
vour in biology. Signalling cascades, starting at the
receptor level, orchestrate a variety of normal or patho-
logical responses via a complex network of kinases,
adaptor molecules, and other signalling proteins [1].
Several gene- and protein-based approaches have
emerged for elucidating the complex intracellular signal-
ling activity. Gene-based analysis has the advantage of
whole genome exploration [2-4] whereas proteomic
approaches are applicable on small pathways but with a
more reliable view of pathway function, since proteins
are the ultimate reporters of cellular activity [5,6]. Both
approaches aim at a holistic understanding of cellular
actions; that is how to link the environmental cues to
the intracellular signalling activity and then to cellular
response [7,8].
Several types of computational models have been pro-
posed to elucidate the complex intracellular signalling
network and are commonly classified as data- or topol-
ogy- driven methods [9,10]. Their main conceptual dif-
ference is their methodology for identifying intracellular
connectivity: data-driven models are highly abstract and
can identify molecular dependencies within experimental
data based on regression analysis, i.e., principal compo-
nent analysis-(PCA), Partial Least Square Regression
(PLSR), Multi-Linear Regression (MLR), Bayesian or
other probabilistic models [11-14]. On the other side,
topology-driven models rely on a-priori knowledge of
the signalling connectivity and depending on their sig-
nal-propagation assumption are classified as physico-
chemical, fuzzy, or logical. In physicochemical models
signalling events are modeled via chemical reactions
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using ordinary or partial differential equations (ODE or
PDE) depending on their ability to model spatial gradi-
ents of signalling molecules [15]. Despite their detailed
representation of the transduction mechanisms, ODE or
PDE -based approaches require a large number of para-
meters, i.e. reaction rate constants and initial conditions,
that makes them practical to very small pathways such
as the EGFR pathway [16]. To overcome that limitation,
fuzzy models have suggested a simplified -but continu-
ous- representation of the transduction mechanism,
which can be applicable to medium-to-large topologies
[17,18]. On the other side of the topology-driven spec-
trum, logical models are based on a simplified (on/off)
representation of the signalling transduction mechanism
and thus, are applicable to very large topologies [19-22].
Logical models derived from canonical pathways have
several mismatches with phosphoproteomic measure-
ments [20] and thus, a genetic algorithm or an Integer
Linear Programming formulation have been developed
to construct cell-specific topologies and identify drug-
induced pathways alterations [18,23,24].
Even though most experimental data conform on a
Cue-Signal-Response (CSR) paradigm [25,26] most of
models -apart from limited cases [18,27]- are capable of
representing events from either cue-to-signals or from
signals-to-responses: topology-driven models are applic-
able on cue-to-signal datasets where a significant body
of literature allows the construction of canonical maps,
where data-driven models are applicable on signal-to-
response datasets where the flow of information is not
fully understandable. Thus, currently there is a lack of
models that can answer how stimuli via their signalling
mechanisms orchestrate diverse cellular responses such
as gene expression, migration, growth, death, metabolic
activity, or cytokine release.
In this paper we present the construction of
“extended” pathway models that aims to explain cellular
responses based on pathway activity. The main idea
behind the computational approach is a hybrid Boolean/
data-driven model where a logical model is used when-
ever a priori knowledge is accessible and a data-driven
approach is used for adding non-canonical edges to
reach out to cellular responses. A previously developed
integer linear programming (ILP) framework [23] is
modified to incorporate non-canonical edges with
weights that correspond to regression coefficients and
used to optimise the connectivity of the hybrid pathway.
The resulting pathway is capable of linking signalling
pathways to any type of quantifiable readout such as
measurements of cell growth, necrosis, apoptosis, cyto-
kine secretion, or transcriptional activity, as long as
these data are available under the same experimental
conditions as the phosphoproteomic dataset. As a case
study, we construct extended pathways for studying
hepatocellular carcinoma (HCC), a liver cancer disease
that is the third leading cause of cancer death with
inadequate therapeutic interventions [28,29]. As cellular
response we choose the release of 22 cytokines and we
ask what signalling activity downstream of 7 receptors,
and 57 signalling molecules can explain the complex
profiles of cytokine releases. Our computational
approach is able to uncover well-known secretion path-
ways and identify significant differences between non-
HCC and HCC cells. Our approach highlights the
importance for construction of integrated CSR pathways
that given a specific stimulus, can predict the intracellu-
lar activity that drives responses such as growth, death,
differentiation, gene expression, or cytokine secretion.
Results and discussion
Construction of CSR Datasets
For the construction of the extended pathways, a CSR
dataset is created using the beads-based ELISA assays of
xMAP technology (Luminex, Austin, TX) as described
in the experimental setup (see Material and Methods)
and shown in Figure 1. Our experimental data consists
of the signalling subset (phosphoproteomic data) and
the response subset (cytokine releases) that were mea-
sured via multi-combinatorial treatments on two cell
types: primary hepatocytes and a hepatocellular carci-
noma cell type known as Huh7 [30]. Approximately 50
different perturbations are imposed to primary and
HCC cells created by the combinatorial treatment of 7
diverse stimuli (+ no stimulus treatment) and 5 inhibi-
tors (+no inhibitor treatment). As pro-growth stimuli,
Tumor Growth Factor alpha (TGFa), Hepatocyte
Growth Factor (HGF) and Heregulin (HER) have been
chosen based on the response yielded on liver cells in
previous experiments [13]. Interleukin 6 (IL6), IL1b and
Tumor Necrosis Factor alpha (TNFa) have been chosen
as inflammatory ligands. In addition, the Insulin (INS)
pathway has been included because of its major role in
liver homeostasis [31]. To better constrain the optimisa-
tion of pathways we impose additional perturbations
using stimuli in combination of selective and potent
inhibitors for MEK, PI3K, cMET, and EGFR/ERBB2
Lapatinib and Erlotinib [32-34]. For each combination
of stimulus and inhibitor, the phosphorylation state of
16 key intracellular proteins and the release of 33 cyto-
kines were measured as detailed in Materials and Meth-
ods section and presented in Additional Files 1 and 2.
Among the cytokines, 22 showed a significant activity in
either primary or Huh7 hepatocytes. These are plotted
in Figure 2 using the DataRail software [35].
Several interesting signalling features can be observed
simply by inspection of the data. As positive control
observations, all inhibitors block their nominal down-
stream targets proving their potency and indicating an
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error-free execution of the multi-combinatorial pipetting
procedure (see numbered stars in Figure 2; star#1:PI3K
inhibitor blocks AKT under any treatment, star#2:MEK
inhibitor blocks ERK under any treatment, star#3:cMET
inhibitor blocks AKT under HGF, star#4:Erlotinib blocks
AKT under TGFa, star#5:Lapatinib blocks AKT under
TGFa). In addition, significant differences can be
observed between the two cell types: Huh7 cells respond
stronger to insulin stimulus by activating the pro-growth
signal AKT and their receptor IRb compared to primary
cells that remain unaffected (Figure 2, star#6). Further-
more, the basal and IL1b -induced phosphorylation
activity of the pro-stress protein HSP27 is higher in
hepatocytes (Figure 2 star#7). With respect to cytokine
data, primary cells appear to respond stronger under
inflammatory stimuli by releasing the inflammatory
cytokines MIP1a and MIP1b under TNFa and IL1b
treatment, an observation that has been seen before as a
mechanisms for HCC cells for evasion of immune sur-
veillance (Figure 2 star#8, star#9). Even though signifi-
cant differences can be observed simply by visual
inspection of the data, the main question remains on
how the cytokine release profile (bottom panels in Fig-
ure 2) can be explained by the pathway activity (upper
panels in Figure 2). An answer to this question is the
presented methodology for construction of extended
pathways that incorporates the pathway activity as well
as the cytokine release outcome.
Computational Framework
The construction of extended signalling pathways can be
divided into three main steps: (a) the construction of
canonical pathways, (b) the identification of new edges
between signals and response from data-driven algo-
rithms, and (c) the optimisation of the extended path-
way using an Integer Linear Programming (ILP)
formulation.
The canonical pathway map (Figure 3a) is created
around the 7 stimuli and the 16 key phosphoproteins
using Ingenuity software (Redwood City, California) and
manual curation based on literature search [23]. Non-
canonical edges (Figure 3c) from key phosphoproteins
to cytokine releases are then added to the generic topol-
ogy and incorporated into the ILP objective function
using stoichiometric representation with weights (in
chemical reactions these are usually referred as “yields”)
that equal to the regression coefficients obtained from a
multi linear regression (MLR) algorithm (see also Mate-
rial and Methods for the detailed formulation). This
strategy allows us to enhance the canonical topology
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Figure 1 Experimental and Computational workflow: (a) The “signalling” dataset monitors the activity of 16 different key phosphoproteins
(blue nodes) under the combinatorial treatment of stimuli (green nodes) and inhibitors (red circles). (b) The response dataset can include any
quantifiable cellular response such as cytokine releases (22 pink nodes) that are monitored under similar treatments. (c) A canonical pathway that
incorporates the stimuli and key phosphoproteins is constructed from the literature (d) Data-driven approach is used to connect the signalling
nodes via “non-canonical” edges to cytokine releases. (e) Canonical and non-canonical edges that fit the experimental data are selected using an
ILP optimisation formulation and thus, the extended pathway topology is constructed.
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with response nodes using non-canonical edges from
data-driven algorithms that have as dependent values
(Y) the cellular response and as independent values (X)
the key phosphoproteins nodes. With this strategy, any
type of data-driven approach can be merged with cano-
nical pathways. Herein, MLR was chosen because of its
simplicity to connect signals to response in an intuitive
way and without the need of intermediate nodes (e.g.
nodes representing principal components if PLSR had
been used).
Once the extended topology is created with canonical
and non-canonical edges, an optimisation formulation
with binary variables and linear constraints is employed
to identify a pool of pathway solutions that best
describes the proteomic data. The main concept behind
the ILP optimisation is the minimization of an objective
function that represents the deviation between the
experimental measurements and the signalling and
response values inferred from the network topology,
penalized by a function of the map’s size. Raw data were
normalized to [0,1] as described previously [24] by tak-
ing into account the experimental noise, the saturation
limits of the assay, and the basal level at time zero (see
also Additional File 3, S1: Data Normalization). There
are three main terms in the ILP objective function as
detailed in Materials and Methods:
∑
j.k
akj |xkj − xk,mj |+
∑
k
∑
jres
akjres |xk,mjres −
∑
ires
zkireswires | +
∑
i
biyi
(1)
The first term penalizes the measurement-prediction
mismatch of the key phosphoproteins and removes all
edges that contradict the “signalling” dataset. The sec-
ond term penalizes the measurement-prediction mis-
match of the response measurements and prunes non-
canonical edges that contradict the response dataset.
The third term removes all edges that have no effect on
the measurement-prediction error and thus penalizes
the map size.
The ILP formulation is solved with the state-of-the-art
commercial code CPLEX through GAMS [36,37]. This
solver guarantees minimal error between experimental
data and the Boolean topology eliminating uncertainty
associated with heuristic methods such as genetic algo-
rithms. To overcome the existence of multiple near-
optimal solutions, in the present work the ILP solver
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Figure 2 Experimental dataset in (a) Huh7 hepatocellular carcinoma cell type and (b) primary hepatocytes. Top panels correspond to
the signalling dataset. Each small subplot consists of two datapoints: the zero “unstimulated” condition and the “early response” which is the
average phosphorylation activity at 5 and 25 minutes post-stimuli treatment. Bottom panels correspond to the response dataset where 22
cytokines were measured 24 hours post-stimuli. The red colour intensity is proportional to the percent increase of the cytokine release as
compared to the basal (unstimulated) condition.
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furnishes 100 distinct solutions within a 10% difference
in the objective value. The resulting pathways are pre-
sented in Figure 3b where the width of each edge corre-
sponds to its frequency in the pool of near-optimal
solutions.
Model Validation
To evaluate the performance of our hybrid model, sev-
eral in-silico tests were performed including comparison
with a data-driven (regression) model (Additional File 3,
S2a/b) and assessment of model sensitivity to i) optimi-
sation parameters, ii) experimental design, iii) data dete-
rioration, iii) generic topology. Detailed validation data
can be found in the Additional File 3 (S2 and S3) but
key points are highlighted in the following section.
Construction of a 2-step Multiple Linear Regression
(MLR) model and comparison to our approach
(Additional File 3, S2)
The performance of our hybrid ILP-MLR approach is
compared against a data-driven 2-step MLR approach
[13] that correlates i) stimuli and inhibitors to the
measured phosphoproteins and ii) phosphoprotein activ-
ities to cytokine releases. The two methods are com-
pared quantitatively for data fitting and qualitatively for
capturing biological insight. Quantitatively, the 2-step
MLR is an unconstrained approach and as such, fits the
experimental data better than the ILP approach as indi-
cated by the measurement - prediction mismatch (12%
for 2-step MLR, 18% for the hybrid ILP-MLR approach).
Qualitatively, the ILP approach predicts the optimal
topology based on the canonical pathway and as such, is
better in uncovering protein connectivity that is sup-
ported by the literature. In contrast the MLR approach
can uncover correlations that lack biological interpreta-
tion, such as Lapatinib induced IRB, MEK1, HSP27 and
P70S6 activation (see Additional File 3, Figure S3).
Overall, most differences in the performance of the
two methods come from the different perspectives they
adopt in constructing signalling pathway. 2-step MLR is
a data driven approach [13,15] aiming at correlating
inputs to outputs ignoring any a-priori knowledge of
protein connectivity. On the other hand, the ILP
Canonical Pathway
Huh7 Hepatocytes 
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Key phosphoproteins signalsSignaling nodesStimuli Receptors Response nodes
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Figure 3 CSR pathways for primary non-HCC hepatocytes and HCC (Huh7) cell types. (a) Generic pathway comprised of canonical edges
extracted from literature (b) non-canonical edges for Huh7 and primary hepatocytes extracted from a data-driven approach (multi linear
regression) (c) extended pathways for Huh7 and primary hepatocytes constructed by fitting canonical and non-canonical edges to experimental
data via an ILP formulation.
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approach attempts to take advantage of the a-priori
knowledge in the literature and make a canonical topol-
ogy to comply with the proteomic data.
Assessment of model sensitivity to changes in experimental
design (Additional File 3, S3.1)
It is apparent that the optimised topology is based on
the experiments performed, the number of signals that
were measured, and the number of perturbations
imposed in the network. More specifically, a single sti-
mulus experiment with only one measured signal can
provide information for a very small subset of the gen-
eric topology, and as such the optimised map will be
very small. On the other hand, an extensive experiment
with all different combinations of stimuli and inhibitors
is not possible due to time and cost limitations. In this
study, we created a dataset that is experimentally feasi-
ble and includes all possible combinations of single sti-
mulus with single inhibitor. Removal of 50% of these
treatments randomly shows a significant deterioration of
the constructed pathway and 35% increase of the fitness
error (see Additional File 3, S3.1). Finding an optimal
experimental design for maximally constraining a gen-
eric topology is a very important aspect in the field of
pathway optimisation that can include pathway controll-
ability, pathway observability, experimental limitations,
and definitely several other experimental constraints
imposed by how the assays are performed.
Assessment of model sensitivity to changes in generic
topology (Additional File 3, S3.2)
Despite the wealth of information found for pathway
construction mainly from pathway databases, conflicting
reports in pathway connectivity makes the construction
of the generic topology a non-trivial task with significant
manual curation and with no guaranteed for the “right”
generic topology. In order to assess the sensitivity of our
hybrid model to changes in the generic topology, we
substitute up to 10% of our generic reactions with ran-
dom reactions. As expected, the optimised pathways are
highly dependent on the generic topologies and with
errors that can go up to ~90% when 10% of reactions
are substituted. A possible way to reduce the sensitivity
to the generic topology is to allow the addition of less
known or conflicting reactions with weight based on lit-
erature findings. However, such a method should be
coupled to a text mining approach and a pathway data-
base which is beyond the scope of this study.
Calibrating the weights of the three objective terms
(Additional File 3, S3.5)
The two prediction mismatch terms were given equal
weights(= 1). In contrast, for the map-size reduction
term a significantly smaller weight was selected (= 1/
20). This weight was chosen based on the longest chain
of consecutive reactions, namely 12, with the purpose to
force the optimiser not to remove edges if they are
essential for satisfying experimental results. For example,
consider a chain reaction R1® R2®...® R12 that
should be kept because experimentally we found the
relation “R1 = 1 implies R12 = 1”. The reward for the
optimiser to satisfy this chain reaction should be more
than the penalty that it has to pay for keeping all 12
reactions. Therefore, if by keeping all reactions the map
size reduction term increases the objective function by
12 units, then the reward for satisfying a chain of 12
reactions (mismatch term) should be higher than 12.
The maximum chain in our pathway is 12 reactions but
we choose 20 in case that further refinements in the
generic topology increase the maximum chain.
Construction of signals-to-response pathways
The generic map includes a total of 7 receptors, 57 sig-
nalling molecules connected with 113 canonical edges,
and 352 non-canonical edges that connect the 16 key
phosphoproteins to the 22 cytokines. From the 352 non-
canonical edges, a large percentage of those have corre-
lation weights close to zero. To minimize the computa-
tional cost of the ILP solution, we choose to retain 60%
of those weights as explained in the Additional File 3,
S3.4. Extended topologies were created for non-HCC
and HCC (Huh7) hepatocytes. The mismatch between
generic pathways and non-HCC or HCC datasets is
41.0% and 46.6% respectively (see Materials and Meth-
ods for definition of error). After optimisation, a total of
47 canonical and non-canonical edges remained in
Huh7 and 43 in non-HCC hepatocytes. The error of the
cell-specific pathways drops to 18% in Huh7 and 17% in
non-HCC hepatocytes. Several edges are removed due
to conflict with the data. One example is the removal of
TNFR ® PI3K edge in both cell types in order to isolate
the AKT and MEK activity from the TNFa stimuli
(star#1, Figure 3). In a similar manner the AKT®
COT® IKK® IKB edges are removed because the mea-
sured AKT and IKB signals are not co-regulated as sug-
gested by the Boolean logic (i.e., AKT = 1 then IKB = 1)
(star#2, Figure 3). Furthermore, the links for activating
p70S6 on a PI3K independent manner remain only on
the primary hepatocytes as suggested by the dataset
(IL1b and TGFa activates p70S6 with or without the
presence of a PI3K inhibitor, star#3, Figure 3).
The presence of cellular response data significantly
enhances the optimisation of the signalling topology in
two different ways. Firstly, non-canonical edges provide
additional pathway information to the ILP formulation.
In other words, the optimiser is forced to conserve
edges that lead to cytokine nodes but do not affect mea-
sured phosphoproteomic signals (see “Impact of
response measurements on pathway optimisation” in
Additional File 3, S4). Secondly, edges with marginal
activations of intracellular signals that otherwise would
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be considered insignificant (either because of assay lim-
itations or time-point selection) are retained in the
topology if they correlate well with cellular response. An
example of this case is the IL6 pathway: although IL6
activation of STAT3 in Huh7 is seemingly undetectable
(see raw signalling data in Figure 2), the IL6® ...®
STAT3 pathway is conserved because even small
chances in the STAT3 activation levels correlate well to
the IL6-induced release of various cytokines (see star#4
in Figure 3) (see “Impact of cellular response measure-
ments on pathway optimisation” in Additional File 3,
S4). Taken together, when the ILP formulation uses
both the phosphorylation and response data, it con-
serves pathways with barely detectable signalling activity
as long as they correlate to cellular response.
The non-canonical edges in Figure 3 show that major
pathways for the release of inflammatory cytokines are
the IL6® STAT3, IL1b® NFkB/p38, and TNFa®
NFkB/p38 pathways [38]. Just three key phosphoprotein
signals (STAT3, Ib and to a lesser extend p38) are
responsible for the release of most inflammatory cyto-
kines including TNFa, GROa, RANTES, MCP1, ILb, and
EOTAXIN (star#4, Figure 3), an observation that is in
accordance to a large body of literature [39]. It is less
known how many different pathways can lead to the
release of a particular cytokine. A simple enumeration
of paths that lead to cytokines for primary hepatocytes
(Figure 3c), shows that more than 50% of the cytokines
are induced by 2 or 3 edges that can be activated by up
to 3 different stimuli following at most 3 different routes
of activation. Since the constructed pathways are small
subsets of the actual pathways, it is obvious that the
mechanisms for a single cytokine secretion are numer-
ous and complex. To tackle such complexity, graph the-
ory analysis of the extended pathways (always limited by
the lack of experimental approaches to decipher the
whole signalling network) can identify central nodes or
group of nodes for inhibiting cytokine secretion, and
thus, increase the efficacy of pharmaceutical interven-
tions. This is in particular applicable for multi-targeting
of STAT3, NFkB, or p38 pathways to achieve anti-
inflammatory effects, a major endeavour of pharmaceu-
tical industry with significant investments on mono-tar-
geted approaches for STAT3, NFkB, or p38 on several
diverse diseases including p38 for rheumatoid arthritis
[40], IB for airway inflammation [41], or STAT3 and
NFkB for HCC [39,42,43].
Independent experimental validation of the model
In order to evaluate the predictive power of our hybrid
model, we asked how well the Huh7 model shown in
Figure 3b captures the correlation of cellular response
to phosphoprotein activity. To achieve that, we choose
the pathways IL1b/TNFa to P38/IKB that play major
role in cytokine secretion, we block them with potent
and selective IKB and P38 inhibitors, and we ask how
well our model can predict the IP10 and RANTES, two
major players for cytokine release. Figure 4 shows the
experimental results and the mismatches with the
hybrid model. Our hybrid model was able to recapitulate
the IP10 release upon introducing IL1b, TNFa or both
in an IKK dependant but p38/HSP27 independent man-
ner. On the other hand, the hybrid model did not fit the
induction of RANTES upon IL1b or TNFa stimulation
probably not because there was no induction (an almost
two fold trend can be seen in the IL1b induced
RANTES) but because the induction does not pass the
0.5 threshold so the logic model to consider it an “ON”
event. This issue highlights the importance of data nor-
malisation: currently data are normalised to the maxi-
mum cytokine value among all treatments. In the follow
up experiments, one treatment is the combination of
IL1b and TNFa where Huh7 cells show a super-induc-
tion of RANTES and makes all other RANTES values to
be considered low. Logic models cannot handle such
non-linear behavior and lead to predictive errors. When
Huh7 treated with the combination of IL1b and TNFa
then the hybrid model was able to perfectly recapitulate
the RANTES release in an IKK dependent and p38/
HSP27 dependent manner.
Conclusions
In the present work, we developed a method for linking
signalling data to cellular response. As a case study, we
compare extended signalling topologies of primary hepa-
tocytes and Huh7. The two pathway maps are signifi-
cantly different. Huh7 are not as responsive as primary
cells since only 17 non-canonical edges exists in Huh7
compared to 28 in primary hepatocytes (see also Addi-
tional File 3, S5 for a comparison of simulation runs for
the two cell types). These findings are in agreement
with recently published data that shows HCC cell types
are less responsive to Toll Like Receptor (TLR) stimuli
than primary hepatocytes [13], presumably to avoid
detection and clearance by the innate immune system
[44-46]. Major pathway differences related to a survival
advantage for HCC can also be observed at the intracel-
lular level: a closer look into the insulin pathway shows
that INS® IRb and INS® IGFR edges are removed in
hepatocytes but the INS® IRb is retained in Huh7
(star#5, Figure 3). A closer look into the raw data (Fig-
ure 1) shows that insulin barely induces IRb and AKT
in primary cells. This is in accordance to recent findings
that shows increased AKT activation correlates well
with the formation of liver tumours [47,48]. However, in
that study, the authors pinpoint the mechanisms of
AKT overactivation to the reduced expression of p85a -
a regulatory subunit of PI3K. Herein, we show that -at
least for the Huh7 case- diminished Akt activation levels
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can be due to receptor’s lower activation as shown from
the phosphorylation of IRb.
Here we presented a method for constructing
extended pathways that start at the receptor level and
via a complex intracellular signalling pathway identify
those mechanisms that drive cellular response. Because
of the nature of response data - where detailed mechan-
isms are sparse and not easily searchable via text mining
approaches- we used a data-driven approach to link
intracellular activity to cellular responses via non-cano-
nical edges. Those edges, together with well-defined
intracellular pathways, were used for the construction of
the “generic map” which is finally optimised to match
high-throughput protein data. The resulting extended
pathways revealed intracellular mechanisms that are
responsible for the release of 22 cytokines and correlate
well with a large body of literature that pinpoint at
STATs and NFB as major drivers of inflammatory sti-
muli. More importantly, comparison between cell types
shows significant differences that lead to survival advan-
tages of the HCC cells. Our results constitute a proof-
of-principle for construction of “extended pathways”
that are capable of linking pathway activity to diverse
responses such as growth, apoptosis, differentiation,
gene expression, or cytokine secretion.
Methods
Experimental procedure
Primary human hepatocytes were isolated and culti-
vated in serum-free Williams’ Medium E (Biochrom
AG, Berlin, Germany) [49]. The viability of isolated
hepatocytes was determined by trypan blue exclusion.
Only cell preparations with a viability > 80% were used
for experiments. The isolated cells were seeded on col-
lagen type I-coated culture dishes at a density of
1.2·105 cells/cm2. Tissue samples from human liver
resection were obtained from patients undergoing par-
tial hepatectomy for metastatic liver tumour secondary
to colorectal cancer. Tumour aggregates were resected
including a safety margin within the normal tissue and
visual inspections from the surgeon confirms that
tumour-free liver tissue was obtained for cell isolation.
Experimental procedures were performed according to
the guidelines of the charitable state-controlled foun-
dation Human Tissue and Cell Research, with the
patient’s informed consent [50], as approved by the
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local ethical committee. The day after isolation, the
primary hepatocytes were cultivated for 2 days in Wil-
liams Medium E supplemented with 2 mm l-glutamine
(Invitrogen), 100 nm dexomethasone (Sigma) and 1%
penicillin ⁄ streptomycin (Invitrogen).
Huh7 cells were plated on 96-well plates coated with
collagen type I-coated (BD Biosciences, Franklin Lakes,
NJ) at approximately 30,000 cells/well in DME medium
containing 10% Fetal Bovine Serum (FBS). After an
overnight incubation, cells were starved for 4 hours,
treated with inhibitors for 40 minutes, and then with
stimuli. In each well different experimental conditions
were imposed by introducing a combination of stimu-
lus and inhibitor. Kinase inhibitors were used at con-
centrations sufficient to inhibit at least 95% of the
phosphorylation of the nominal target as determined
by dose-response assays in previous work [13]. The fol-
lowing concentrations were chosen: EGFR/Lapatinib (3
μM), EGFR/Erlotinib (1 μM), cMET/JNJ38877605 (1
μM), MEK/PD325901 (100 nM), PI3K/PI-103 (10 μM),
p38 (100 nM), IKK/IMD (10 μM). After 40 minutes of
incubation with the inhibitors, the cells were treated
with saturated levels of 7 stimuli: IL1b (10 ng/ml), INS
(2 μM), IL6, TGFA (100 ng/ml), TNFa (100 ng/ml),
HGF (100 ng/ml), HER (100 ng/ml) in two separate
plates for 5 and 25 minutes. The selection of these two
time points was based on preliminary results published
in [13], that identified 5 and 25 minutes as the optimal
reporters of early phosphorylation activities. At the
end of the treatment cell lysates were collected using
standard lysate procedure [13]. Lysates from 5 and 25
minutes were pooled together in 1:1 ratio. The mixed
lysate -that corresponds to an “average early signalling
response"- was measured using the Luminex xMAP
technology. Mixing cell lysates serves multiple pur-
poses such as significant decrease of experimental cost
and improvement of data quality [23]. The following
phosphoprotein bead set from Bio-Rad were used: Akt
(Ser473), CREB (Ser133), ERK1/2 (Thr202/Tyr204,
Thr185/Tyr187), GSK3(Ser21/Ser9) Histone H3
(Ser10), HSP27 (Ser78), IB-a (Ser32/Ser36), IR-b
(Tyr1146), IRS-1Ser (Ser636/Ser639), JNK (Thr183/
Tyr185), MEK1 (Ser217/Ser221), p38 (Thr180/Tyr182),
p70S6K (Thr421/Ser424), STAT3 (Ser727), p90RSK
(Thr359/Ser363), IGF-1R (Tyr1131).
Apart from the phosphoprotein signals, cytokine
release was also measured from supernatants under
the same experimental conditions. After incubating the
cells with the inhibitors for 45 minutes, the same sti-
mulus/inhibitor combinations were applied and follow-
ing overnight incubation we removed the supernatant
and measured the secretion of 33 cytokines. Among
the 33 cytokines, 22 cytokines were shown an activity
and were used in the subsequent data analysis. The
cytokines used are: bFGF, Eotaxin, GMCSF, IFNg,
IL15, IL17, IL1b, IL1ra, IL2, IL4, IL6, MCP1, MIP1a,
MIP1b, IP10, GROa, ICAM, GCSF, RANTES, TNFa,
VEGF, SDF1. The 11 cytokines that were excluded are:
IL9, IL10, IL12p70, IL13, IL5, IL7, IL8, PDFG, MIF,
MIG, VCAM1.
Computational Procedure
Data Processing and Linear Regression Analysis
Both signalling and response datasets were organized
in data structures in the form of 5-D cubes using the
DataRail software [35]; 4 of the dimensions of the cube
correspond to the different experimental conditions
(cell type, time point, stimuli treatment, inhibitor treat-
ment) and the 5th to the measured readouts (response
data and signalling data). The raw data for both
response and signalling datasets were then normalized
using a hill function filter and scaled to the range [0,1]
as described previously [24] (See Additional File 3, S1
for an assessment of the proposed method’s sensitivity
to variables of the normalization procedure). The noise
level of the assay has been estimated in [13] at the
range of 166 fluorescent units, by considering the stan-
dard deviation of repeated measurements of unstimu-
lated controls. The response matrix YRes (an m × k
matrix representing m response component under k
conditions) was then regressed against the signalling
matrix XSig (an m × k matrix representing m intracel-
lular signals under k conditions). The computed corre-
lation matrix W is comprised by the correlation
coefficients wi,j, where i is the index of response com-
ponents (i = 1..num_res) and j the index of signals (j =
1..num_sig). The correlation coefficients wi,j, were then
used as the stoichiometric weights of the non-signal-
ling reactions in the Boolean framework that originates
from a signal j and ends to a response component i
(see also ILP formulation section and Additional File 3,
S3 for an estimation of the proposed method’s sensitiv-
ity to wi,j ).
ILP Formulation
Non-signalling edges The ILP formulation first used to
optimise Boolean signalling pathways in [23], is
extended herein to include response measurements.
The main concept revolves around the minimisation of
an objective function that represents the deviation
between the experimental measurements and the
values inferred from the network topology penalized
by a function of the map’s size. The ILP prunes the
pathway by removing all edges that contradict the
respective dataset, thereby minimizing the value of the
objective function:
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∑j.k
akj |xkj − xk,mj |+
∑
k
∑
jres
akjres |xk,mjres −
∑
ires
zkireswires | +
∑
i
biyi
(2)
where the summation is only over the relevant terms
as described below.
Major addition to the formulation, compared to the
one introduced in [23], consists the set jres = {1,...,ns,res}
of response species, and the set ires = {1,...,nr,res} of edges
linking signalling (j) with response (jres) nodes. The rest
of the used symbols are as follows:
- akj , a
k
jres , bi ≥ 0 , are weights set by the user,
- xkj is the predicted value of species j in the experi-
ment k,
- xk,mj , x
k,m
jres
is the measured value of species j in
experiment k,
- zki = 0 ∨ zki = 1denotes the activation or not of
reaction i in experiment k.
- yi, is a variable denoting whether a reaction is pos-
sible or not yi = 0 ∨ yi = 1.
- The term
∑
ires
zkireswiresjres corresponds to xkjres and is
the predicted value of response species jres in experi-
ment k. It equals to the sum of all reactions ires lead-
ing to species jres weighted by wiresjres , i.e., the
Multiple Linear Regression weights. In other words
the summation is only over the reactions i that lead
to response species j.
Therefore, the first term of the objective function∑
j.k
akj |xkj − xk,mj | , corresponds to the measurement-
prediction mismatch over all signalling species (j) and
experimental conditions (k). Note that the summation is
only taken over the species j that are measured in
experiment k.
The second term
∑
k
∑
jres
akjres |xk,mjres −
∑
ires
zkireswiresjres | , cor-
responds to the measurement-prediction mismatch over
all response species (jres) and experimental conditions
(k). The middle summation is over the response species
j that are measured in experiment k. The inner sum-
mation is over the reactions i that lead to response
species j.
The third term
∑
i
biyi , corresponds to the penalty
imposed by the map size. For a complete reference to
the original formulation see [23]. Here we will only dis-
cuss the extra constraints regarding the response spe-
cies. An extensive assessment of the proposed method’s
performance under different values of akjres and wires is
illustrated in Additional File 3, S3.
Concerning the term
∑
k
∑
jres
akjres |xk,mjres −
∑
ires
zkireswiresjres | ,
assuming akj ≥ 0 , |x
k,m
jres
−
∑
ires
zkireswiresjres | ∈ [0, 1] corre-
sponds to the scaled measurement-prediction error. Let
the minimal and maximal total yields (and thus
expected measurements) of the species be given by
vmin =
∑
ires,wiresjres<0
zkireswiresjres
vmax =
∑
ires,wiresjres≥0
zkireswiresjres
We want to minimize the weighted sum of the abso-
lute differences dˆ
k
jres = |xk,mjres −
∑
ires
zkireswiresjres | . Assuming
that the measurement is consistent with the weights, we
would have xk,mjres ∈ [vmin, vmax] which would give
dˆkjres ∈ [0, vmax − vmin]. However, this cannot always
be assumed and therefore we take the more general case
that
dˆkjres ∈ [0, dˆk,maxjres ],
dˆk,maxjres = max{vmax, x
k,m
jres } − min{vmin, x
k,m
jres }
We can thus scale as
dkjres dˆ
k,max
jres
= |xk,mjres −
∑
ires
zkireswiresjres |
to
dkjres dˆ
k,max
jres
≥ xk,mjres −
∑
ires
zkireswiresjres
dkjres dˆ
k,max
jres
≥ −xk,mjres +
∑
ires
zkireswiresjres
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and obtain the desired range, i.e., dkj ∈ [0, 1] . To
ensure linearity we impose two inequality constraints,
which are equivalent for akj ≥ 0 ,
−dkjres dˆk,maxjres −
∑
ires
zkireswiresjres ≤ −xk,mjres
−dkjres dˆk,maxjres +
∑
ires
zkireswiresjres ≤ −xk,mjres
The above constraints complete the formulation.
Solution pool As aforementioned, the objective function
(1) consists of three major terms, namely∑
j.k
akj |xkj − xk,mj | and
∑
k
∑
jres
akjres |xk,mjres −
∑
ires
zkireswiresjres |
which are related to the goodness of fit, and
∑
i
biyi
which penalises the size of the pathway. The need for the
third term arises from the fact that there are many solu-
tions fitting the measurements equally good. To reduce
the number of optimal solutions the size of the pathway is
also minimised. However, the biological significance
underlying the minimisation of the pathway’s size is not
evident. Thus, we introduce a tolerance of the global mini-
mum and harvest 100 solutions lying within this tolerance.
This modification allows us to consider a solution pool
instead of a single solution. The frequency of each edge in
the solution pool, expresses a level of confidence in the
presence or absence of the respective edge in the optimal
pathway. By taking into account suboptimal solutions we
are sure to capture relations between the signalling cas-
cades, and their probability of occurrence, that we might
otherwise miss.
Error Calculation
The error is defined as the deviation between experi-
mental and simulated values using the following for-
mula:
Error =
∑
j.k
|xkj − xk,mj |
xk,mj
xkj , is the predicted value of species j in the experi-
ment k,
xk,mj , is the measured value of species j in experiment k,
Additional material
Additional file 1: Signalling dataset. Dataset in MIACA format
(phosphorylation data) that were produced and used in this manuscript
(see also figure 2).
Additional file 2: Response dataset. Dataset in MIACA format that
were produced and used in this manuscript (see also figure 2).
Additional file 3: Supplementary Materials and Methods.
“Supplementary Materials and Methods” include further information
about the proposed methodology, such as, i) data normalisation
procedure used, ii) comparison with an alternative 2-step Multiple Linear
Regression method, iii) a detailed model assessment and iv) comparison
of simulation runs for Huh7 and Normal cells.
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